Takeda Pharmaceutical Co., Ltd.
 
 
 
 
公司概覽
業務類別 --
業務概覽 Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
公司地址 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
電話號碼 +81 332782306
傳真號碼 +81 332782268
公司網頁 https://www.takeda.com
員工數量 47029
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Andrew S. Plump, M.D.,PhD Director and President, Research and Development 日圓 12.00M 17/06/2026
Mr. Marcello Agosti Interim Head, Strategy and Portfolio Development -- 17/06/2026
Ms. Teresa Marie Bitetti President, Global Oncology Business Unit -- 17/06/2026
Mr. Milano Furuta Director and Chief Financial Officer 日圓 119.00M 17/06/2026
Ms. Julie Kim Chief Executive Officer, President and Director -- 17/06/2026
Mr. Giles Platford President, International Business Unit -- 17/06/2026
Ms. Lauren Duprey Chief Transformation Officer -- 17/06/2026
Mr. Gabriele Ricci Chief Data and Technology Officer -- 17/06/2026
Ms. Akiko Amakawa Chief Executive Officer Chief of Staff -- 17/06/2026
Ms. Asuka Miyabashira President, Japan Pharma Business Unit -- 17/06/2026
Ms. Elaine Shannon President, Global Supply and Quality -- 17/06/2026
Dr. Awny Farajallah, M.D. Chief Medical Officer -- 17/06/2026
Ms. Natalie Furney Global General Counsel -- 17/06/2026
Ms. Nicola Greenway Chief Human Resources Officer -- 17/06/2026
Dr. Rhonda Pacheco, PhD President, U.S. Business Unit and U.S. Country Head -- 17/06/2026
Mr. Ramy Riad President, Plasma-Derived Therapies Business Unit -- 17/06/2026
Ms. Jennifer Smoter Chief Communications and Governance Officer -- 17/06/2026
 
董事會成員
董事會 職務 更新日期
Mr. Bruce D. Broussard Independent Director 17/06/2026
Dr. John M. Maraganore,PhD Independent Director 17/06/2026
Dr. Steven Gillis, PhD Independent Director 17/06/2026
Dr. Paulus Stoffels, M.D. Independent Director 17/06/2026
Dr. Andrew S. Plump, M.D.,PhD Director and President, Research and Development 17/06/2026
Mr. Milano Furuta Director and Chief Financial Officer 17/06/2026
Ms. Julie Kim Chief Executive Officer, President and Director 17/06/2026
Ms. Kimberly A. Reed Independent Director 17/06/2026
Mr. Masami Iijima Chairman of the Board 17/06/2026
Ms. Miki Tsusaka Independent Director 17/06/2026
Mr. Koichiro Kimura Independent Director 17/06/2026
 
所屬ETF (更新日期: 25/07/2026 04:52)
代號 名稱 佔比% 持有日期
IEFAiShares Core MSCI EAFE ETF0.73%30/06/2026
EWJiShares MSCI Japan ETF0.44%30/06/2026
EFAiShares MSCI EAFE ETF0.36%30/06/2026
BBJPJPMorgan BetaBuilders Japan ETF0.32%30/06/2026
DXJWisdomTree Japan Hedged Equity ETF0.23%30/06/2026
VEUVanguard FTSE All-Wld ex-US ETF0.23%30/06/2026
DFIVDimensional International Value ETF0.23%30/06/2026
SCHFSchwab International Equity ETF™0.22%30/06/2026
FNDFSchwab Fundamental International Eq ETF0.15%30/06/2026
EFAViShares MSCI EAFE Min Vol Factor ETF0.14%30/06/2026
IXUSiShares Core MSCI Total Intl Stk ETF0.13%30/06/2026
SPDWState Street® SPDR® Ptf Dev Wld exUS ETF0.12%30/06/2026
EFViShares MSCI EAFE Value ETF0.11%30/06/2026
VYMIVanguard Intl Hi Div Yld Idx ETF0.11%30/06/2026
IDEViShares Core MSCI Intl Dev Mkts ETF0.11%30/06/2026
JIREJPMorgan International Rsrch Enh Eq ETF0.09%30/06/2026
VTVanguard Total World Stock ETF0.08%30/06/2026
GCOWPacer Global Cash Cows Dividend ETF0.08%30/06/2026
EFGiShares MSCI EAFE Growth ETF0.08%30/06/2026
ICOWPacer Dev Mkts Intl Csh Cows 100 ETF0.07%30/06/2026
 1    2    3    4    5    6    7    8  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.